NovoCure Limited (NVCR) Stock

NovoCure Limited (NVCR) is a Healthcare stock trading at $14.25 (as of 2026-06-18), with a market capitalization of $1.97B and a trailing P/E of -11.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NovoCure Limited develops, manufactures, and commercializes tumor treating fields (TTFields) devices used to treat solid tumor cancers. Its offerings include Optune for glioblastoma and Optune Lua for malignant pleural mesothelioma, which are used across the United States, Europe, the Middle East, Africa, Japan, and Greater China.

Valuation — source: SEC EDGAR (first-party)
Price$14.25
Market Cap$1.97B
P/E Ratio-11.1
EV / EBITDA-12.3
Price / Book5.97
Price / Sales2.93
DCF Value (model)$-12.13
DCF Upside vs Price-185.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$655.35M
Net Margin-20.8%
Return on Equity-52.3%
Debt / Equity0.59
Current Ratio2.90
Revenue Growth (YoY)8.3%
EPS Growth (YoY)-21.8%
FCF Growth (YoY)9.3%
Financial Health — source: SEC EDGAR
Altman Z-Score0.67 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Stock P/E-11.1
Sector P/E (Healthcare)21.0
Industry P/E (Medical Equipment)31.7
vs Sector-153.1%
vs Industry-135.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($186.05M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOFrank Leonard
Employees1,488
CountryJE
IPO Date2015-10-01

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Cadre Holdings, Inc. (CDRE)
  • AxoGen, Inc. (AXGN)
  • Enovis Corporation (ENOV)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Beta Bionics, Inc. (BBNX)
  • CONMED Corporation (CNMD)
  • IRadimed Corporation (IRMD)
  • KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
NVCR earnings history · NVCR institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.